Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX) has earned an average rating of “Moderate Buy” from the fifteen analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $30.2727.

Several equities research analysts have weighed in on BCAX shares. Guggenheim started coverage on Bicara Therapeutics in a report on Monday, May 11th. They set a “buy” rating and a $42.00 price target on the stock. HC Wainwright increased their price objective on Bicara Therapeutics from $40.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. The Goldman Sachs Group increased their price objective on Bicara Therapeutics from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Citizens Jmp restated a “market outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, Morgan Stanley boosted their target price on Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX opened at $26.87 on Monday. The stock’s 50-day moving average is $22.15 and its two-hundred day moving average is $19.34. Bicara Therapeutics has a 1-year low of $8.57 and a 1-year high of $27.98. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -9.67 and a beta of -0.54.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Equities research analysts anticipate that Bicara Therapeutics will post -3.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Raben sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $22.88, for a total transaction of $125,840.00. Following the completion of the sale, the insider owned 55,286 shares in the company, valued at $1,264,943.68. The trade was a 9.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $23.61, for a total value of $354,150.00. Following the sale, the chief executive officer owned 362,152 shares of the company’s stock, valued at approximately $8,550,408.72. The trade was a 3.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,900 shares of company stock worth $1,420,704 in the last three months. 13.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Cantor Fitzgerald L. P. purchased a new position in Bicara Therapeutics during the 3rd quarter worth approximately $1,579,000. UBS Group AG grew its stake in Bicara Therapeutics by 97.4% during the 4th quarter. UBS Group AG now owns 192,191 shares of the company’s stock worth $3,235,000 after buying an additional 94,829 shares during the last quarter. Cinctive Capital Management LP purchased a new position in Bicara Therapeutics during the 3rd quarter worth approximately $661,000. American Century Companies Inc. purchased a new position in Bicara Therapeutics during the 2nd quarter worth approximately $103,000. Finally, Larson Financial Group LLC grew its stake in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after buying an additional 3,595 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.